DK3042205T3 - Fremgangsmåde til forbedring af antistofstabilitet - Google Patents

Fremgangsmåde til forbedring af antistofstabilitet Download PDF

Info

Publication number
DK3042205T3
DK3042205T3 DK14758893.3T DK14758893T DK3042205T3 DK 3042205 T3 DK3042205 T3 DK 3042205T3 DK 14758893 T DK14758893 T DK 14758893T DK 3042205 T3 DK3042205 T3 DK 3042205T3
Authority
DK
Denmark
Prior art keywords
antibody stability
improving antibody
improving
stability
antibody
Prior art date
Application number
DK14758893.3T
Other languages
English (en)
Inventor
Hubert Kettenberger
Stefan Klostermann
Apollon Papadimitriou
Florian Lipsmeier
Jasmin Sydow-Andersen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK3042205T3 publication Critical patent/DK3042205T3/da

Links

Classifications

    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10RNA viruses
    • C07K16/102Coronaviridae (F)
    • C07K16/104Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20Protein or domain folding
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16CCOMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C99/00Subject matter not provided for in other groups of this subclass
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Evolutionary Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Computing Systems (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK14758893.3T 2013-09-06 2014-09-03 Fremgangsmåde til forbedring af antistofstabilitet DK3042205T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13183389 2013-09-06
EP13184174 2013-09-12
PCT/EP2014/068649 WO2015032776A1 (en) 2013-09-06 2014-09-03 Method for improving antibody stability

Publications (1)

Publication Number Publication Date
DK3042205T3 true DK3042205T3 (da) 2020-03-02

Family

ID=51485608

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14758893.3T DK3042205T3 (da) 2013-09-06 2014-09-03 Fremgangsmåde til forbedring af antistofstabilitet

Country Status (10)

Country Link
US (2) US10418126B2 (da)
EP (2) EP3761033A3 (da)
JP (1) JP6580570B2 (da)
KR (1) KR20160052562A (da)
CN (1) CN105518461B (da)
CA (1) CA2918191A1 (da)
DK (1) DK3042205T3 (da)
MX (1) MX2016002720A (da)
RU (1) RU2711719C2 (da)
WO (1) WO2015032776A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014306867B2 (en) 2013-08-12 2017-10-26 Genentech, Inc. Compositions and method for treating complement-associated conditions
EP3137503A1 (en) 2014-05-01 2017-03-08 Genentech, Inc. Anti-factor d antibody variants and uses thereof
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
WO2017075252A1 (en) * 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
WO2021025940A1 (en) * 2019-08-02 2021-02-11 Genentech, Inc. Prediction of side-chain degradation in polymers through physics based simulations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US100736A (en) * 1870-03-15 dundeedale
RU2134724C1 (ru) * 1992-08-24 1999-08-20 Ниссин Сокухин Кабусики Кайся Гуманизированное антитело и способ его получения, полинуклеотид (варианты), гибридомная клеточная линия (варианты)
US8278262B2 (en) * 2004-09-21 2012-10-02 Biontech Ag Use of microproteins as tryptase inhibitors
KR101516823B1 (ko) * 2006-03-17 2015-05-07 바이오겐 아이덱 엠에이 인코포레이티드 안정화된 폴리펩티드 조성물
IN2009DN05758A (da) * 2007-03-12 2015-07-24 Esbatech Ag
PL3241843T3 (pl) * 2008-06-25 2021-12-27 Novartis Ag Optymalizacja rozpuszczalności cząsteczek immunowiążących
US9598682B2 (en) * 2009-09-29 2017-03-21 Vib Vzw Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose
EP3119490B1 (en) * 2014-03-21 2021-09-08 F. Hoffmann-La Roche AG In vitro prediction of in vivo half-life of antibodies
EP3122762A1 (en) * 2014-03-28 2017-02-01 Novozymes A/S Enzyme variants and polynucleotides encoding same
CA2950273C (en) * 2014-05-30 2022-06-21 Novozymes A/S Variants of gh family 11 xylanase and polynucleotides encoding same

Also Published As

Publication number Publication date
HK1223684A1 (zh) 2017-08-04
RU2016111352A3 (da) 2018-05-23
RU2016111352A (ru) 2017-10-11
EP3761033A2 (en) 2021-01-06
CA2918191A1 (en) 2015-03-12
MX2016002720A (es) 2016-06-08
WO2015032776A1 (en) 2015-03-12
US10418126B2 (en) 2019-09-17
US20200066372A1 (en) 2020-02-27
EP3042205A1 (en) 2016-07-13
CN105518461B (zh) 2018-04-13
US20160275238A1 (en) 2016-09-22
CN105518461A (zh) 2016-04-20
EP3042205B1 (en) 2019-12-25
JP6580570B2 (ja) 2019-09-25
RU2711719C2 (ru) 2020-01-21
EP3761033A3 (en) 2021-01-20
JP2016530288A (ja) 2016-09-29
KR20160052562A (ko) 2016-05-12

Similar Documents

Publication Publication Date Title
IL243311A0 (en) Novel antibody frameworks
DK3083540T3 (da) Fremgangsmåde til fremstilling af substituerede phenoxyphenylketoner
DK3336106T3 (da) Anti-fcrh5-antistoffer
EP3083682C0 (en) DOUBLE SPECIFICITY ANTIBODIES
DK3708583T3 (da) Ikke-fucosylerede anti-fgfr2iiib-antistoffer
LT3049441T (lt) Anti-pdl1 antikūnų kompozicija
FI20135292L (fi) Menetelmä kartongin valmistamiseksi
DK3071595T3 (da) Humaniseret anti-kallikrein-2-antistof
DK2972353T3 (da) Forbedrede fremgangsmåder til udførelse af multipleksanalyser
DK3016991T3 (da) Sammensætninger til formning af væsker
DK3300610T3 (da) Fremgangsmåde til fraktionering af opløselige ærter
DK2969098T3 (da) Fremgangsmåder til oprensning af antistoffer
DK3068800T3 (da) FcRn-specifikke antistoffer
DK3332813T3 (da) Metode til opregulering af antigenekspression
DK3033708T3 (da) Fremgangsmåde til evaluering af et dokument
BR112015021083A2 (pt) método
DK2983680T3 (da) Forbedring af organer til transplantation
HRP20190085T1 (hr) Anti-cd52 protutijela
DK3065774T3 (da) Anti-CCL17-antistoffer
DK3083493T3 (da) Fremgangsmåde til fremstilling af syntesegas
BR112015029076A2 (pt) método
DK3024576T3 (da) Fremgangsmåde til opstart af en fischer-tropsch-proces
DK3016682T3 (da) Metoder til behandling af kræft
DK2786852T3 (da) Metode til laminering af rørfolie
FI20135361L (fi) Analyyttinen menetelmä